Cancer Research Cell Death Mechanisms and Cancer Therapy  Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ito, H.
Right arrow Articles by Whang, E. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ito, H.
Right arrow Articles by Whang, E. E.
[Cancer Research 64, 7439-7446, October 15, 2004]
© 2004 American Association for Cancer Research


Regular Articles

Prostaglandin E2 Enhances Pancreatic Cancer Invasiveness through an Ets-1-Dependent Induction of Matrix Metalloproteinase-2

Hiromichi Ito, Mark Duxbury, Eric Benoit, Thomas E. Clancy, Michael J. Zinner, Stanley W. Ashley and Edward E. Whang

Department of Surgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts

Accumulating evidence suggests an important role for cyclooxygenase-2 (COX-2) in the pathogenesis of a wide range of malignancies. Here we tested the hypothesis that the COX-2 product prostaglandin E2 (PGE2) increases cellular invasive potential by inducing matrix metalloproteinase-2 (MMP-2) expression and activity through an extracellular signal-regulated kinase (ERK)/Ets-1-dependent mechanism in pancreatic cancer. PANC-1 and MIAPaCa-2 pancreatic cancer cells were treated with PGE2 or rofecoxib, a selective COX-2 inhibitor. MMP-2 expression and activity were assayed using Western blot analysis and zymography, respectively. MMP-2 promoter activity was analyzed with a luciferase-based assay. Ets-1 activity was analyzed using gel shift assay. Ets-1 expression was specifically silenced using RNA interference. Cellular invasive and migratory potentials were determined using a Boyden chamber assay with or without Matrigel, respectively. Exogenous PGE2 induced MMP-2 expression and activity and increased ERK1/2 phosphorylation, Ets-1 binding activity, and MMP-2 promoter activity. PGE2 also increased cellular migratory and invasive potentials. The mitogen-activated protein kinase kinase inhibitor PD98059 and Ets-1 silencing each abolished PGE2-induced increases in MMP-2 expression. PD98059 and Ets-1 silencing each abrogated the effect of PGE2 on cellular invasive potential but not on cellular migratory potential. Rofecoxib suppressed MMP-2 expression and activity, Ets-1 binding activity, MMP-2 promoter activity, and cellular migratory and invasive potentials. These results suggest that PGE2 mediates pancreatic cancer cellular invasiveness through an ERK/Ets-1-dependent induction of MMP-2 expression and activity. They also suggest that COX-2 inhibition may represent a strategy to inhibit invasive potential in pancreatic cancer.




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
I.-C. Lo, T.-M. Lin, L.-H. Chou, S.-L. Liu, L.-W. Wu, G.-Y. Shi, H.-L. Wu, and M. J. Jiang
Ets-1 mediates platelet-derived growth factor-BB-induced thrombomodulin expression in human vascular smooth muscle cells
Cardiovasc Res, March 1, 2009; 81(4): 771 - 779.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
J.-H. Chen, H.-H. Lin, T.-A. Chiang, J.-D. Hsu, H.-H. Ho, Y.-C. Lee, and C.-J. Wang
Gaseous Nitrogen Oxide Promotes Human Lung Cancer Cell Line A549 Migration, Invasion, and Metastasis via iNOS-Mediated MMP-2 Production
Toxicol. Sci., December 1, 2008; 106(2): 364 - 375.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
T. Adachi, M. Yamamoto, and M. Suematsu
Targeting NAD(P)H Oxidase: Ets-1 Regulates p47phox
Circ. Res., November 9, 2007; 101(10): 962 - 964.
[Full Text] [PDF]


Home page
Circ. Res.Home page
W. Ni, Y. Zhan, H. He, E. Maynard, J. A. Balschi, and P. Oettgen
Ets-1 Is a Critical Transcriptional Regulator of Reactive Oxygen Species and p47phox Gene Expression in Response to Angiotensin II
Circ. Res., November 9, 2007; 101(10): 985 - 994.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Jain, G. Chakraborty, and G. C. Kundu
The Crucial Role of Cyclooxygenase-2 in Osteopontin-Induced Protein Kinase C {alpha}/c-Src/I{kappa}B Kinase {alpha}/{beta}-Dependent Prostate Tumor Progression and Angiogenesis.
Cancer Res., July 1, 2006; 66(13): 6638 - 6648.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
G. K. Yiu and A. Toker
NFAT Induces Breast Cancer Cell Invasion by Promoting the Induction of Cyclooxygenase-2
J. Biol. Chem., May 5, 2006; 281(18): 12210 - 12217.
[Abstract] [Full Text] [PDF]


Home page
Jpn J Clin OncolHome page
J. H. Byun, M. A. Lee, S. Y. Roh, B. Y. Shim, S. H. Hong, Y. H. Ko, S. J. Ko, I. S. Woo, J. H. Kang, Y. S. Hong, et al.
Association between Cyclooxygenase-2 and Matrix Metalloproteinase-2 Expression in Non-Small Cell Lung Cancer
Jpn. J. Clin. Oncol., May 1, 2006; 36(5): 263 - 268.
[Abstract] [Full Text] [PDF]


Home page
ReproductionHome page
Q. Li, F. Jimenez-Krassel, Y. Kobayashi, J. J Ireland, and G. W Smith
Effect of intrafollicular indomethacin injection on gonadotropin surge-induced expression of select extracellular matrix degrading enzymes and their inhibitors in bovine preovulatory follicles.
Reproduction, March 1, 2006; 131(3): 533 - 543.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
L. M. Backhus, N. A. Petasis, J. Uddin, A. H. Schonthal, R. D. Bart, Y. Lin, V. A. Starnes, and R. M. Bremner
Dimethyl celecoxib as a novel non-cyclooxygenase 2 therapy in the treatment of non-small cell lung cancer
J. Thorac. Cardiovasc. Surg., November 1, 2005; 130(5): 1406 - 1412.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
F. G. Bottone Jr., Y. Moon, J. S. Kim, B. Alston-Mills, M. Ishibashi, and T. E. Eling
The anti-invasive activity of cyclooxygenase inhibitors is regulated by the transcription factor ATF3 (activating transcription factor 3)
Mol. Cancer Ther., May 1, 2005; 4(5): 693 - 703.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.